SRC and plasma cell myeloma: In contrast, pretreatment with 2.5 μM SKI1, a Src inhibitor, significantly attenuated EGCG-induced decrease in viability of U266 human multiple myeloma cells (p < 0.05, Student’s t test) as shown in Figure 1A.